AI Healthcare

Pathos AI raises $237 million as Bristol Myers Squibb and Tempus join neuroscience research

Reuters (via KELO-AM)Oct 23, 2026

Pathos AI secured $237 million at an approximately $3 billion valuation while announcing neuroscience-focused AI collaborations with Bristol Myers Squibb and Tempus.

Pathos AI announced on October 23 that it raised $237 million in a Series E round led by Bristol Myers Squibb, valuing the drug-development company at approximately $3 billion. The company also disclosed collaborations with Bristol Myers and Tempus AI to apply its AI platform to Alzheimer’s disease and other neurological conditions.

Under the arrangement, Tempus plans to assemble a de-identified, longitudinal dataset covering hundreds of thousands of patients with neurological conditions. Pathos will license the data under a five-year, $55 million agreement and use its Foundry platform to analyze disease biology and inform the design of clinical trials. Bristol Myers gains non-exclusive access to Foundry across its broader research portfolio, plus three-year exclusive rights to use the platform for neuroscience development programs.

Pathos says Foundry uses thousands of specialized AI agents to synthesize clinical, genomic and biological data, alongside information about other drug-development efforts. The company describes the system as a tool for guiding decisions about drug programs and trials; the announcement does not establish that its AI has improved treatment outcomes or produced an approved medicine.

The financing will also support Pathos’s oncology pipeline, which the company says has four active clinical assets. A key stated priority is advancing JSKN-016, a TROP2/HER3 bispecific antibody-drug conjugate, toward registrational studies. Funds are also earmarked for other programs, including an experimental breast-cancer drug partnered with AstraZeneca.

The deal brings together a sizable financing round and a new use of Pathos’s AI platform beyond oncology. The neurological dataset and collaborations are intended to support research and trial planning, but any resulting treatments would still need to demonstrate safety and efficacy through clinical testing.

Industry Impact

AI enters neuroscience drug development

Biotechnology, pharmaceuticals, clinical research

Overview

Pathos AI’s $237 million financing and collaborations with Bristol Myers Squibb and Tempus extend its drug-development platform into neuroscience. Tempus plans to provide a de-identified longitudinal dataset covering hundreds of thousands of patients; Pathos will license it for five years for $55 million and use Foundry to analyze disease biology and inform trial design. For pharma leaders and researchers, the deal offers a concrete model for combining patient data with AI-supported research. Its impact on treatment development remains unproven, and resulting therapies would still need clinical testing.

Key Impact Points

The Tempus agreement gives Pathos access to a large longitudinal neurological dataset for research and trial planning.

Bristol Myers Squibb receives broader non-exclusive access to Foundry and three-year neuroscience exclusivity.

The financing also supports Pathos’s oncology pipeline, including plans to advance JSKN-016 toward registrational studies.

Opportunities

AI-supported clinical research

Pharmaceutical R&D, neuroscience, clinical trials

The announced arrangement demonstrates a specific opportunity for pharmaceutical companies to combine longitudinal patient data with AI analysis when investigating disease biology and planning clinical trials. Pathos will license Tempus’s de-identified neurological dataset for five years for $55 million, while Bristol Myers Squibb gains platform access and neuroscience exclusivity. Other organizations may assess similar data-and-platform collaborations, but the article does not establish that Foundry improves trial performance or treatment outcomes. Any adoption would require careful evaluation of dataset coverage, research usefulness, and clinical validation. The deal provides evidence of a commercial licensing model, not proof of broader demand or a guaranteed return.

Neurological disease research and trial planning
Problem: Drug developers need to analyze disease biology and inform clinical-trial design for neurological conditions.
Solution: Pathos plans to apply its Foundry platform to Tempus’s de-identified longitudinal patient dataset.
Target Users: Pharmaceutical research and clinical-development teams working on neuroscience programs.
Business Value: The collaboration provides access to patient data and AI-supported analysis for research and trial planning; clinical benefit is not yet established.
Revenue Potential: The announced five-year data license is worth $55 million, demonstrating a commercial agreement but not establishing revenue potential for other providers.

Reference link

https://kelo.com/2026/10/23/pathos-ai-teams-up-with-bristol-myers-and-tempus-ai-to-advance-drug-development

Image Source Link

https://www.reuters.com/resizer/v2/ZBHICN6WSVJ75IWCAZRSV5HK3E.jpg?auth=92387d21d67730c8ea1ea6d8a0b6e3ce89bfaa5745dcd0ac11d55a0575b9b731&width=1920&quality=80

Community Discussion (0)

No discussions yet. Be the first to start the conversation!